Comorbidity of Generalized Anxiety Disorder and Substance Use Disorders

Analucía A. Alegría, Deborah S. Hasin, Edward V. Nunes, Shang-Min Liu, Carrie Davies, Bridget F. Grant, Carlos Blanco

2010-09-15articleThe Journal of Clinical Psychiatry115 citationsgreen

No readable copy stored yet — this record is metadata only.

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes Substance Abuse Treatment and Outcomes Mental Health Treatment and Access

Abstract

Article AbstractObjective: Prior research has consistently documented a strong association between generalized anxiety disorder (GAD) and substance use disorder (SUD). Comorbidity of GAD and SUD (GAD-SUD) represents clinical challenges, as the patients†symptoms are often more severe and are frequently prolonged, making their management more complex when compared with individuals with GAD only. The purpose of this study was to examine whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates.Method: Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093). Diagnoses were made using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version.Results: We found that the lifetime prevalence rate of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%. Individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD. Treatment-seeking rates for GAD are equally low in individuals with GAD-SUD and GAD-NSUD. Both groups were as likely to receive pharmacologic treatment for anxiety.Conclusions: The findings of our study indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and that GAD-SUD is associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and higher use of alcohol and drugs to relieve anxiety symptoms.J Clin Psychiatry 2010;71(9):1187-1195Submitted: May 4, 2009; accepted August 14, 2009. (doi:10.4088/JCP.09m05328gry).Corresponding author: Bridget F. Grant, PhD, Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, MS 9304, 5635 Fishers Lane, Bethesda, MD 20892-9304 (bgrant@willco.niaaa.nih.gov).

Citations in this library

Stored only when both papers are in the corpus — 115 citations exist upstream.

References

2005Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

2005Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

1967The social readjustment rating scale

1999The Structure of Common Mental Disorders

2004Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

1994DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey

2003Life Event Dimensions of Loss, Humiliation, Entrapment, and Danger in the Prediction of Onsets of Major Depression and Generalized Anxiety

2005Influence of Psychiatric Comorbidity on Recovery and Recurrence in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder: A 12-Year Prospective Study

Cited by

2013Service Use and Barriers to Mental Health Care Among Adults With Major Depression and Comorbid Substance Dependence